Veeva Systems Inc. Class A Common Stock (VEEV)

FairStock Score: 48/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett-Graham investor, I start with business quality and then ask what price is being paid. Veeva supplies cloud software to life sciences, a specialized niche where deep customer integration can create switching costs. The filed numbers show real momentum: in fiscal Q2 2027, the quarter ended 2026-07-31, revenue was $928.0M and net income was $273.4M, or $1.66 diluted EPS, versus revenue of $789.1M and net income of $200.3M in fiscal Q2 2026, the quarter ended 2025-07-31. For FY2026, the year ended 2026-01-31, revenue was $3.2B, net income was $908.9M, and diluted EPS was $5.44. That is a high-quality growth record, with low debt (D/E 0.02), a Piotroski F-score of 7/9, an Altman Z-score of 21.09, and trailing free cash flow of $1.7B. FairStock computes ROE at 14.42% and ROCE at 7.58%, so returns are decent but not spectacular after capital. The trouble is price. At the 2026-10-26 close of $318.18, FairStock shows a P/E of 52.25, P/B of 7.10, EV/EBITDA of 47.09, PEG of 1.45, and FCF yield of only 3.2%. Its Graham Number is $79.32, leaving a margin of safety of -307.26%. The Lynch category is STALWART, based on 19.1% five-year profit growth and 16.9% revenue growth. This is a fine business, but the quote already discounts much of the good news; I would want a wider discount before calling it a value opportunity.

In plain English: Veeva Systems makes cloud software used by life-sciences companies. The business looks strong: sales and profits are rising, it earns high profit margins, and it carries very little debt. At the recent share price, however, the market is already paying a high price for those profits, so the stock looks expensive rather than cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2027 10-Q (period ended 2026-07-31) · fiscal Q1 2027 10-Q (period ended 2026-04-30) · fiscal Q3 2026 10-Q (period ended 2025-10-31) · fiscal Q2 2026 10-Q (period ended 2025-07-31) · FY2026 10-K (period ended 2026-01-31) · FY2025 10-K (period ended 2025-01-31) · FY2024 10-K (period ended 2024-01-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer